In mouse models of multiple myeloma, pharmacologic inhibition of Notch signaling with a novel bone-targeted gamma-secretase inhibitor (BT-GSI) decreased RANKL expression and had potent anti-resorptive effects, similar to those seen with bisphosphonates [57]. The gene discussed is TNFSF11; the disease is plasma cell myeloma.